DOW CHEMICAL CO /DE/
For the period ended Dec 31, 2025. Filed Feb 3, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Feb 3, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 16. Form 10-K Summary
| Dow Inc. and Subsidiaries | |
| The Dow Chemical Company and Subsidiaries | |
| Valuation and Qualifying Accounts | Schedule II |
| (In millions) For the years ended Dec 31, | 2025 | 2024 | 2023 |
|---|---|---|---|
| Accounts Receivable - Allowance for Doubtful Receivables | |||
| Balance at beginning of year | $95 | $81 | $110 |
| Additions charged to expenses 1 | 23 | 28 | 21 |
| Deductions from reserves 2 | (59) | (14) | (50) |
| Balance at end of year | $59 | $95 | $81 |
| Inventory - Obsolescence Reserve | |||
| Balance at beginning of year | $88 | $70 | $57 |
| Additions charged to expenses | 14 | 27 | 20 |
| Deductions from reserves 3 | (2) | (9) | (7) |
| Balance at end of year | $100 | $88 | $70 |
| Reserves for Other Investments and Noncurrent Receivables | |||
| Balance at beginning of year | $1,650 | $1,751 | $1,950 |
| Additions charged to expenses 4 | 5 | 14 | 31 |
| Deductions from reserves 5 | (214) | (115) | (230) |
| Balance at end of year | $1,441 | $1,650 | $1,751 |
| Deferred Tax Assets - Valuation Allowance | |||
| Balance at beginning of year | $2,748 | $2,948 | $1,269 |
| Additions charged to expenses 6 | 633 | 55 | 1,864 |
| Deductions from reserves | (331) | (255) | (185) |
| Balance at end of year | $3,050 | $2,748 | $2,948 |
Additions included a $23 million reclassification from "Reserves for Other Investments and Noncurrent Receivables" in 2024.
Deductions included write-offs, recoveries, currency translation adjustments and other miscellaneous items, including a $23 million reclassification to "Reserves for Other Investments and Noncurrent Receivables" in 2023.
Deductions included disposals and currency translation adjustments.
Additions included a $23 million reclassification from "Accounts Receivable - Allowance for Doubtful Receivables" in 2023.
Deductions included $81 million related to the Company’s investment in DowAksa, which was converted to cash in 2025. See Note 4 to the Consolidated Financial Statements for additional information. Deductions also included a $23 million reclassification to "Accounts Receivable - Allowance for Doubtful Receivables" in 2024, $143 million related to the Company's investment in a previously held equity method investment, which was converted to cash, in 2023, and $77 million in 2025, 2024 and 2023 related to the Company's investment in Sadara. See Note 11 to the Consolidated Financial Statements for additional information.
Additions in 2023 include increases in valuation allowances related to foreign tax assets that are expected to expire without being utilized.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.